Literature DB >> 10092960

Interchangeability and predictive performance of empirical tolerance models.

M Gårdmark1, L Brynne, M Hammarlund-Udenaes, M O Karlsson.   

Abstract

Models of tolerance are commonly derived on empirical grounds, because of lack of knowledge about the mechanism of tolerance or because of the difficulty of appropriately simplifying complex physiological processes. The present study was performed to evaluate the interchangeability of tolerance models used in the literature and to address some determinants for selection of an appropriate design and data analysis strategy. Seven models were chosen (noncompetitive antagonist model, partial agonist model, reverse agonist model, direct moderator model, indirect moderator model, pool model and adaptive pool model) along with their corresponding parameter estimates, representing a wide range of empirical models. The performance of the models on various data sets was evaluated. Data were simulated from each original model and were further analysed by the other models. The effect-time course of each and every data set could be described well by at least 2 different empirical tolerance models, but no model could describe all the data sets adequately. However, all models could adequately describe at least 2 different data sets. This indicates that, without additional knowledge or assumptions, it is unlikely that reliable mechanistic information can be deduced from the mere fact that 1 (or more) of these models can describe the data. Generally, data expressing only limited tolerance can be described by a wide variety of models, whereas few models will be appropriate for data characterised by extensive tolerance. The models that gave an adequate description of a data set were selected for further study that investigated their predictive capacity based on the parameters previously determined. Predictions were made for 4 different administration schemes. The selected models gave similar predictions for the extended designs of 3 data sets for which the original study designs characterised tolerance well. For the other 4 data sets, the selected models gave disparate predictions, although the models described the original data set well. Thus, the predictive capability of a model was linked to the original study design, whereas the correlation between predictive performance and the type of model was weak or absent. Based on the results, factors of importance for the design and evaluation of studies of tolerance were identified and discussed.

Mesh:

Year:  1999        PMID: 10092960     DOI: 10.2165/00003088-199936020-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  40 in total

1.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.

Authors:  M Wakelkamp; G Alván; J Gabrielsson; G Paintaud
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

2.  Aspects on tail-flick, hot-plate and electrical stimulation tests for morphine antinociception.

Authors:  M Gårdmark; A U Höglund; M Hammarlund-Udenaes
Journal:  Pharmacol Toxicol       Date:  1998-12

Review 3.  Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence.

Authors:  S M Johnson; W W Fleming
Journal:  Pharmacol Rev       Date:  1989-12       Impact factor: 25.468

4.  Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver.

Authors:  Z X Xu; Y N Sun; D C DuBois; R R Almon; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

5.  Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: timing performance deficits.

Authors:  C E Lau; A C Heatherington
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

6.  Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat--pharmacokinetic/pharmacodynamic modelling.

Authors:  M Gårdmark; M Hammarlund-Udenaes
Journal:  Pain       Date:  1998-02       Impact factor: 6.961

7.  A model eliciting transient responses.

Authors:  E B Ekblad; V Licko
Journal:  Am J Physiol       Date:  1984-01

8.  Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling.

Authors:  M Gardmark; M O Karlsson; F Jonsson; M Hammarlund-Udenaes
Journal:  J Pharm Sci       Date:  1998-07       Impact factor: 3.534

9.  A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers.

Authors:  P Francheteau; J L Steimer; H Merdjan; M Guerret; C Dubray
Journal:  J Pharmacokinet Biopharm       Date:  1993-10

10.  Kinetics of cocaine distribution, elimination, and chronotropic effects.

Authors:  M J Chow; J J Ambre; T I Ruo; A J Atkinson; D J Bowsher; M W Fischman
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

View more
  13 in total

1.  Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation.

Authors:  Franziska Schaedeli; Maria Pitsiu; Neal L Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

2.  Assessment of basic indirect pharmacodynamic response models with physiological limits.

Authors:  Zhenling Yao; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04       Impact factor: 2.745

3.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

4.  Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials.

Authors:  Ahmed A Othman; Wolfram Nothaft; Walid M Awni; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

5.  Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.

Authors:  Ezra E W Cohen; Kehua Wu; Christine Hartford; Masha Kocherginsky; Kimberly Napoli Eaton; Yuanyuan Zha; Anitha Nallari; Michael L Maitland; Kammi Fox-Kay; Kristin Moshier; Larry House; Jacqueline Ramirez; Samir D Undevia; Gini F Fleming; Thomas F Gajewski; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

Review 6.  The efficiency concept in pharmacodynamics.

Authors:  G Alván; G Paintaud; M Wakelkamp
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

7.  Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.

Authors:  Iñaki F Trocóniz; Ilonka Zsolt; María J Garrido; Marta Valle; Rosa M Antonijoan; Manel J Barbanoj
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

8.  Modeling cardiac uptake and negative inotropic response of verapamil in rat heart: effect of amiodarone.

Authors:  Pakawadee Sermsappasuk; Osama Abdelrahman; Michael Weiss
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

9.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

10.  Modelling acute tolerance to the EEG effect of two benzodiazepines.

Authors:  Harald Ihmsen; Sven Albrecht; Werner Hering; Jürgen Schüttler; Helmut Schwilden
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.